	6	7	6
	4		

* /			Application Number	09/928,213		
<u> 47.7</u>	SMITTAL		Filing Date	August 10, 2001		
<i>)</i> / F	ORM		First Named Inv ntor	SHANKARA, Srinivas		
(to be used for all corr	respondence after init	ial filing)	Group Art Unit	1646		
			Examiner Name	Unassigned		
otal Number of Pages	in This Submission	26	Attorney Docket Number	GA0197C		
		ENCL	OSURES (check all that apply)			
Fee Transmittal Fo	om duplicate)		ment Papers Application)	After Allowance Communication to Group		
Fee Attached	aupiicate)	☐ Drawin	g(s)	Appeal Communication to Board of Appeals and Interferences		
Amendment / Resp	ponse	Licens	ing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final		Petition	า	Proprietary Information		
Affidavits/decla	aration(s)		n to Convert to a onal Application	Status Letter		
			of Attorney, Revocation e of Correspondence Address	Other Enclosure(s) (please identify below):		
Express Abandonn	ment Request	Termin	al Disclaimer	Supplemental PTO Form 1449 (1 sheet); copies of three (3) cited		
Supplementa Information Disclos	· ·		st for Refund	references; and Return Postcard		
		∐ CD, Nu	ımber of CD(s)			
Certified Copy of P Document(s)	Priority	Rema	rks	RECEIV		
Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing UN 1 8 2003						
Response to Missing Parts under 37 CFR						
1.52 or 1.53	OFR			R AGENT TECH CENTER		
	SIGNAT	URE OF	APPLICANT, ATTORNEY, O	R AGENT		
Firm or Individual name	Elizabeth Lassen Genzyme Corporation 15 Pleasant Street C					
muividuai fiame	P.O. Box 9322 Framingham, Massa	ichusetts 0	V101-9322			
Signature Elijaluth Tass						
Date	June 13, 2003	<u> </u>				
		CFI	RTIFICATE OF MAILING			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

June 13, 2003

Signature

Complete if Known

09/928,213

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

Ę.	<u> </u>	7/11			~ L	Applic	cation Nu	mber	09/92	28,213	
for FY 2003 Effective 9/91/2003. Patent fees are subject to annual revision.					Filing Date			Augu	August 10, 2001		
						Named Ir	ventor	SHA	NKARA JUN	† 1-8-2 90	
					Exam	iner Nam	ne	Unas	sigend		
Applic	nt claims s	mall enti	ity status	. See 37	7 CFR 1.27		/ Art Un		1646		NTER 1600
TOTAL AM	OUNT OF P	AYMEN	т (\$)	180		Attorr	ney Dock	et No.	GA0 ²	197C	
	METHOD OF P	AVMENT	(check all	that anniv	.	1			FFF C	ALCULATION (continued)	
		ATTIMETOT	(oncon an i	шаг арргу	,	3. AD	DITIONAL	. FEES		The Committee	
☐ Check ☐	Credit card		ey 🗌 Ot	.her 🔲 N	None	Larne	Entity	Small I	Entity		
☑ Deposit Acc	count:	Orde	er								
Deposit						Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Account	07-1074					1051	130	2051	65	Surcharge - late filing fee or oath	
Number	L					1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
Deposit	25115141					1053	130	1053	130	Non-English specification	
Account Name	GENZYM	IE CORPOR	KATION .			1812	2,520	1812	2,520	For filing a request for reexamination	├
he Commissi	oner is auth	orized to:	(check all	that apply	<i>,</i>	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(Charge any Charge any	s) indicated b additional fee	elow 🔯 (e(s) during	Credit any the pende	overpaymency of this	ents application	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
☐ Charge fee(filing fee	•	1251	110	2251	55	Extension for reply within first month	
the above-ide		EE CALCU				1252	410	2252	205	Extension for reply within second month	
BASIC	FILING FEE					1253	930	2253	465	Extension for reply within third month	
arge Entity	Small Entit	_				1254	1,450	2254	725	Extension for reply within fourth	
ee Fee Code (\$)	Fee Fe		Description	1	Fee Paid	1255	1,970	2255	985	Extension for reply within fifth month	
001 750	2001 37		y filing fee	ſ		1401	320	2401	160	Notice of Appeal	
002 330	2002 16	•	gn filing fee	. •		1402	320	2402	160	Filing a brief in support of an appeal	
003 520	2003 26	_	filing fee	İ		1403	280	2403	140	Request for oral hearing	
004 750	2004 37	5 Reiss	sue filing fee	-		1451	1,510	1451	1,510	Petition to institute a public use proceeding	
005 160	2005 80	Provi	isional filling) tee [1452	110	2452	55	Petition to revive - unavoidable	
	SUBT	OTAL (1)		ſ	(\$) 0	1453	1,300	2453	650	Petition to revive – unintentional	
						1501	1,300	2501	650	Utility issue fee (or reissue)	
. EXTRA CLA	AIM FEES	Extr		ee from	Fee	1502	470	2502	235	Design issue fee	
		Clai		elow	Paid	1503	630	2503	315	Plant issue fee	<u> </u>
tal Claims	-20 **	= 0	x [= 0	1460	130	1460	130	Petitions to the Commissioner	.
ependent	-3 **	= 0			= 0	1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	· — — •
ims						1806	180	1806	180	Submission of Information Disclosure Stmt	180
pendent arge Entity	ı Small I	Entity	×L		= 0	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
ee Fee		Fee	Eas D	-4:		1809	750	2809	375	Filing a submission after final rejection	,
Code (\$)	Code	(\$) <u>F</u>	Fee Descrip						-	(37 CFR § 1.129(a))	
202 18	2202		Claims in ex			1810	750	2810	375	For each additional invention to be	
201 84	2201				excess of 3					examined (37 CFR § 1.129(b))	├ ──┤ │
203 280					im, if not paid nt claims over	1801	750	2801	375	Request for Continued Examination (RCE)	,
204 84	2204	42 o	original pate	ent	cess of 20 and	1802	900	1802	900	Request for expedited examination of a design application	
205 18	2205		over original		COSS OF ZU dIN	Other f	fee (speci	ξ υ\			H
		SUBTO	OTAL (2)	(\$) 0		Outer 1	ee (speci	·y/	-		
		232.0	· · · · · · · · · · · · · · · · · · ·			*Redu	iced by Ba	asic Filin	a Fee P:	aid SUBTOTAL (3) (\$) 18	
**or number =	roviouely seid	if groots	r: Eor Dois	euge co-	abovo	,,,,,,,,	uy De		9,000	SUBTUTAL (3) (\$) 18	0
**or number p	eviously paid	, ii greater	, FOI REIS	sues, see	anove	L					
SUBMITTED BY	<u> </u>									Complete (if applicable)	

WARNING: Information on this form may become public. Credit card information should not be

Registration No. Attorney/Agent)

Name (Print/Type)

Signature

Included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

31,845

Telephone

Date

508-270-2553

June 13, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application for: Shankara et al.

Examiner: Unassigned

JUN 1 8 2003

RECEIVED

Serial No.: 09/928,213

Group Art Unit: 1646

TECH CENTER 1600/2900

Filing Date: August 10, 2001

or: ANTIGENIC PEPTIDE CONCATOMERS

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to Commissioner for Patents (Vashington, D.C. 20231) Dated: Name of Person Certifying: Printed Name: Taryn Antalek		Certificate of First-Class Mailing (37 C.F.R. § 1.8(a))
mail on the date indicated below in an envelope addressed to Commissioner for Patents (Vashington, D.C. 20231) Dated: WWW 13, 2013 Name of Person Certifying: WWW WHALLE	I hereby certify that this paper	and all enclosures are being deposited with the United States Postal Service as first class
	mail on the date indicated bel	ow in an envelope addressed to Commissioner for Patents (Washington, D.C. 20231
Printed Name: Taryn Antalek	Dated: WWW 15, AVI	
		Printed Name: Taryn Antalek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

	With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
	Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
□ F1 0000010	Before the mailing date of a first Office Action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any fees required pursuant to 37 C.F.R. § § 1.17(p) or 1.17(i)(1).

06/16/2003 YPOLITE1 00000106 071074 01 FC:1806 180.00 DA

This Information Disclosure Statement is filed:

X After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever comes first, and the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for the fee (\$180.00) set forth in 37 C.F.R. § 1.17(p) and any additional required fees. This Information Disclosure Statement is filed: After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement. The undersigned certifies that: Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56 more than three months prior to the filing of this Information Disclosure Statement. II. Copies of the Cited Items: \boxtimes Copies of all of the items listed on the attached Form PTO-1449 are enclosed. Copies of only the following items listed on the attached Form PTO-1449 are enclosed: Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. _ and relied upon in this application for an earlier filing

date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).

Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1449 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- 3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. **07-1074** for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

DATE: <u>0//3/03</u>

Elizabeth Lassen

Registration No. 31,845

Genzyme Corporation 15 Pleasant Street Connector P.O. Box 9322 Framingham, Massachusetts 01701-9322

Telephone: (508) 270-2553 Facsimile: (508) 872-5415

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C mplete if Kn wn **Application Number** 09/928,213 Filing Date August 10, 2001 First Named Inventor SHANKARA, Srinivas Group Art Unit 1646 **Examiner Name** Unassigned Attorney Docket Number GA0197C

(use as many sheets as necessary)

Substitute for form 1449A/PTO

of 1 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	HEEMSKERK, M. et al., "Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells", Cellular Immunology, 1999, 195:10-17	
	2	TOES, R. et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion", The Proceeding of the National Academy of Science, December 1997, 94:14660-14665	
	3	WHITTON, J. et al., "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal- Dose Virus Challenge", Journal of Virology, January 1993, 348-352	
		RECE!	/ED
		RECEN	2003
		JUN 1"	
		TECH CENTER	1600/2

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.